Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Nonterminal Albumin Fusions for Improved Delivery of Polypeptides

Award Number: F31EB037447
ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 05/01/2026
PERIOD OF PERFORMANCE END DATE: 04/30/2028

Group Awards By:

View Award Description

Nonterminal Albumin Fusions for Improved Delivery of Polypeptides - PROJECT SUMMARY/ABSTRACT Polypeptides, due to their high affinity and selectivity for diverse biological targets, hold significant promise as therapeutic agents for treating complex diseases such as cancer, metabolic disorders, and infectious diseases. However, poor pharmacokinetics (PK), including rapid renal clearance and protease degradation, often hinders their clinical applications. This leads to short half-lives and limited bioavailability, necessitating frequent dosing and increasing the burden on the patient and the risk of side effects. Existing strategies to improve PK, such as recombinant fusions to the N- or C-terminus of human serum albumin (HSA) or chemical modifications to constrain conformation like cyclization, frequently compromise the biological activity and manufacturability of these therapeutic agents. This project aims to avoid activity losses due to the steric hindrance from the albumin fusion partner while constraining conformation naturally by developing a novel platform that nonterminally fuses polypeptides to albumin. Nonterminal fusions are relatively unexplored due to the challenges associated with maintaining the native folding and function of the fusion partner. However, recent advancements in structural prediction tools now enable us to accurately predict and mitigate these disruptions. We hypothesize that nonterminally fusing polypeptide cargoes to albumin at externally presented disulfide-constrained loop regions will significantly improve their pharmacokinetic properties without compromising their activity. We will evaluate this strategy for the ability to enhance the stability, half-life, and target localization of therapeutic polypeptides through three specific aims: Aim 1 will establish an expression system and leverage a model peptide to screen potential insertion sites for structural perturbations and availability. Aim 2 will use AlphaFold to develop a computational pipeline to predict structural changes due to nonterminal fusions, establishing rules for generalizing the strategy to any payload. Aim 3 will evaluate the PK properties and therapeutic benefits of nonterminal fusions of Neo-2/15, an engineered IL-2/15 receptor agonist, in cancer models. Successful completion of this project will yield a robust platform for nonterminally fusing polypeptides to albumin, offering a modular and generalizable strategy to improve drug activity, half-life, and target tropism. This approach has the potential to significantly advance the fields of protein engineering and drug delivery. By establishing a precedent and pipeline for nonterminal fusions across any carrier proteins, more effective and durable treatments can be developed in many therapeutic areas and indications, ultimately improving patient outcomes and enhancing public health.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $46,484 )
2026	2026	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	1033 MASSACHUSETTS AVE STE 3	CAMBRIDGE	MA	02138	MIDDLESEX	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	1	5/4/2026	NEW	$0
2026	2026	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	1033 MASSACHUSETTS AVE STE 3	CAMBRIDGE	MA	02138	MIDDLESEX	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	1	4/22/2026	NEW	$46,484
														Subtotal = $46,484

Grand Total All Awards = $46,484

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Nonterminal Albumin Fusions for Improved Delivery of Polypeptides

Award Number: F31EB037447

ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 05/01/2026

PERIOD OF PERFORMANCE END DATE: 04/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer